Search Within

Hani Hassoun

Formats
  1. Meeting Abstract (232)
  2. Journal Article (90)
  3. Research Letter (9)
  4. Correspondence (4)
  5. Book Section (2)
  6. Review (2)
Groups
  1. Center for Hematologic Malignancies (339)
  2. Department of Medicine (339)
  3. Hematologic Malignancies, Division of (339)
  4. Myeloma (339)
  5. Survivorship Research (253)
  6. Bone Marrow Transplant (241)

More Groups

People
  1. Heather Landau (224)
  2. Sergio Giralt (205)
  3. Alexander Lesokhin (202)
  4. David Chung (166)
  5. Neha Korde (166)
  6. Sham Mailankody (163)

More People

Years
  1. 2025 (7)
  2. 2024 (35)
  3. 2023 (37)
  4. 2022 (36)
  5. 2021 (21)
  6. 2020 (28)

More Years

Publications
  1. Blood (133)
  2. Clinical Lymphoma, Myeloma and Leukemia (51)
  3. Journal of Clinical Oncology (27)
  4. Biology of Blood and Marrow Transplantation (19)
  5. Leukemia and Lymphoma (14)
  6. American Journal of Hematology (10)

More Publications

Publishers
  1. American Society of Hematology (141)
  2. Elsevier Inc. (74)
  3. American Society of Clinical Oncology (27)
  4. Nature Publishing Group (24)
  5. Taylor & Francis Group (21)
  6. John Wiley & Sons, Inc. (10)

More Publishers

Results (339)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Difference in involved and uninvolved free light chain (dFLC) of less than 1mg/dL early post risk adapted melphalan and autologous stem cell transplantation (RA-ASCT) predicts renal response (RR) at 1 year in light chain (AL) amyloidosis
    Meeting Abstract

    Purvey, S.; Seier, K.; Devlin, S. M.; Ruiz, J. D.; Maloy, M. A.; Shah, G. L.; Hassoun, H.; Giralt, S. A.; Landau, H. J.
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: A Tri-State Transplant Consortium study
    Correspondence

    Hassoun, H.; Bayer, R.; Devlin, S.; Gentile, T.; Becker, M.; O’Dweyer, K.; Lesser, M.; Landau, H.; Chung, D.; Giralt, S.
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Pilot study of bortezomib and dexamethasone pre- and post-risk-adapted autologous stem cell transplantation in AL amyloidosis
    Journal Article

    Landau, H.; Lahoud, O.; Devlin, S.; Lendvai, N.; Chung, D. J.; Dogan, A.; Landgren, C. O.; Giralt, S.; Hassoun, H.
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • A phase 1/2 study to assess safety and dose of ixazomib in combination with cyclophosphamide and dexamethasone in newly diagnosed patients with light chain (AL) amyloidosis
    Meeting Abstract

    Sanchez, L.; Landau, H. J.; Rosenbaum, C. A.; Abrahams, A.; Chin, C.; Liotta, B.; Agudo, N.; Ramnath, S.; Hoover, E.; Rahman, H.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Difference in involved and uninvolved free light chain (dFLC) of less than 1mg/DL early post risk adapted melphalan and autologous stem cell transplantation (RA-ASCT) predicts renal response at 1 year in light chain (AL) amyloidosis
    Meeting Abstract

    Purvey, S.; Seier, K.; Devlin, S. M.; Ruiz, J. D.; Maloy, M. A.; Shah, G. L.; Hassoun, H.; Giralt, S. A.; Landau, H. J.
    Blood (2019)

    Fulltext@MSK | Save
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save